This page shows the latest Periodic Fever Syndrome news and features for those working in and with pharma, biotech and healthcare.
Immunotherapeutic expands in rare Periodic Fever Syndrome conditions. Novartis' anti-inflammatory therapy Ilaris (canakinumab) has received new US approvals for its use in three rare Periodic Fever Syndrome conditions. ... Its label now includes Tumor
and older, adding to its current use in the rare genetic disorder cryopyrin-associated periodic syndromes (CAPS). ... Other uses being assessed include tumour necrosis factor receptor-associated periodic syndrome (TRAPS), colchicine-resistant familial
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
No results were found
Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ of experience, Innovative Trials deploys...